Description: Analysis of the projected impact of the Affordable Care Act on Medicare Part C revenue over 2014 through 2017, with background on recent historical revenue trends. The analysis is largely based on CMS published data, with trend analysis based on the Medicare Trustees report and author's assumptions.

Description: This article, an Honorable Mention Essay for the Society of Actuaries' Entrepreneurial Actuaries Section 2010 Papers Competition, is a discussion of the various issues relating to measurement of data in healthcare. The author presents “a light hearted & tongue-in-cheek take on how healthcare is typically measured, and an entrepreneurial vision for a better world.” Noting that typically data is summarized in deterministic models that produce point estimates for analysis and decision making, the author’s vision presented in the paper “is that of a central repository of actuarially modeled distributions that can either be used as benchmarks or adapted to an organization's experience.”

Description: The author reviews the impact of health care exchanges becoming operational in 2014, and he offers ideas for efficient risk identification and ways to measure the results.

Description: Essay suggests reforms of the U.S. health care system to promote financial soundness, broader access, and efficient operations. These reforms require that each participant in the system – individuals, employers, providers, insurers, and government – give a little.

Description: The Society of Actuaries' health leadership met earlier this year for an all-day meeting in Chicago. A significant portion of that meeting was spent discussing current challenges facing the U.S. health care system and how the SOA can best serve its members by addressing top priority issues. The Actuary Magazine, April/May 2005

Description: The big event of 2023 is the launch of multiple Humira biosimilars, which began in January with the arrival of Amgen’s Amjevita on the market. The launch of Amjevita kicks off the process of changing the specialty drug marketplace in the United States. The expectation of the full impact of this big event is very hopeful, but there is still uncertainty several months after its beginning. Humira is the highest-selling drug in the world and has been since 2013 (Figure 1)—except for when COVID-19 projects temporarily surpassed it. The world is eagerly awaiting the launch of multiple biosimilar drugs to compete with Humira and hopefully bring more competitive pricing to the benefit of payers and patients everywhere.

Description: This session is about the Health insurance has become an important issue in this year's presidential election campaign. What effect will this have on the likelihood of major health-care reform, on public expectations about rights to health care, about perceptions of health insurers, etc? From Record of Society of Actuaries Vol. 18, No. 4A.

Description: Presented at June 1996 Spring Meeting. This session provides a description of several state purchasing alliances and their experience to date.

Description: Brief discussion of future anticipated health reform and information on papers discussing these reforms. Topics include Medicare, individual insurnace, tax credits & subsidies, pre-Medicare retirees and Medicaid

Description: Panel examines the actuarial, business, clinical, and ethical issues attached to physician-owned health plans in which the physicians are both providers and investors. From the Record of the Society of Actuaries, Vol. 24, No. 3.